Respiratory syncytial virus vaccine - BioComo
Alternative Names: BC-0004; BC-007(Back-up); BC-PIV/RSV F; RSV vaccine - BioComoLatest Information Update: 28 Oct 2024
At a glance
- Originator BioComo
- Developer BioComo; Mie University; Rockefeller University
- Class Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in Japan (Intranasal)
- 28 Oct 2022 No recent reports of development identified for research development in Respiratory-syncytial-virus-infections(Prevention) in Japan (IM, Injection)
- 15 Sep 2020 Pharmacodynamics data from a preclinical study in Respiratory syncytial virus infections released by BioComos